Abstract: Polymer-drug conjugates have significantly influenced polymer therapeutics over the last decade via controlled pharmacokinetics. Dapsone (4,4'-diamino diphenylsulphone) is not only widely used in the treatment of leprosy but forms an essential component in the treatment of autoimmune inflammatory diseases and malaria. However, its low bioavailability and non-specific distribution in the body leads to absorption throughout organs including skin, liver, and kidneys that can cause serious side effects. Thus, in this study we report the synthesis of polymer-drug conjugates of dapsone covalently bonded to macromolecular chains towards the development of new bioactive polymeric formulations with anti-inflammatory properties. Dapsone was functionalised with an acrylic moiety in which the acrylamide residue was directly bonded to one of the aromatic rings of dapsone. This functionalization yielded an unsymmetrical dapsone methacrylamide (DapMA) structure, which on free radical polymerisation and co-polymerisation with HEMA yielded polymers of hydrocarbon macromolecules with pendant dapsone units. Thermal and size-exclusion chromatographic analysis revealed an increase in thermal stabilisation of the homopolymer (p(DapMA)) in comparison to the copolymer (p(Dap-co-HEMA)) with relatively high average molecular weight. The polymer conjugates exhibited high stability with low dapsone release from the polymeric backbone due to hydrolysis. However, a significant anti-inflammatory activity in a nitric oxide inhibition assay confirmed that this property was the consequence of only the macromolecular composition and not related to the release of low molecular weight compounds. Thus, the conjugation of dapsone to macromolecular systems provides a synthetic route to incorporate this drug into polymeric systems, facilitating their development into new anti-inflammatory therapies
acrylamide residue was directly bonded to one of the aromatic rings of dapsone. This functionalization yielded an unsymmetrical dapsone methacrylamide (DapMA) structure, which on free radical polymerisation and co-polymerisation with HEMA yielded polymers of hydrocarbon macromolecules with pendant dapsone units.
Thermal and size-exclusion chromatographic analysis revealed an increase in thermal stabilisation of the homopolymer (p(DapMA)) in comparison to the copolymer (p(Dap-co-HEMA)) with relatively high average molecular weight. The polymer conjugates exhibited high stability with low dapsone release from the polymeric backbone due to hydrolysis. However, a significant anti-inflammatory activity in a nitric oxide inhibition assay confirmed that this property was the consequence of only the macromolecular composition and not related to the release of low molecular weight compounds. Thus, the conjugation of dapsone to macromolecular systems provides a synthetic route to incorporate this drug into polymeric systems, facilitating their development into new anti-inflammatory Introduction During the last century, sulfone derivatives have been extensively used in medicine because of their versatile bioactive, biocidic and anti-inflammatory properties. Dapsone is structurally one of the simplest sulfones but also recognised as an active therapeutic agent from this family of compounds. As an antibiotic, dapsone acts against bacteria and protozoa inhibiting the synthesis of dihydrofolic acid through competition with para-aminobenzoate for the active site of dihydropteroate synthease [1] . In addition, dapsone has been successfully used as an essential component for the treatment and prophylaxis of leprosy, actinomycetoma, Pneumocystis pneumonia, and malaria. The anti-inflammatory action of the drug is not related with its antibacterial action and is still not fully understood. Dapsone has been reported to interfere with the activation or function of a large number of polymorphonuclear leukocytes, predominantly neutrophils and eosinophils, into the affected tissue and shows a noticeable activity in reducing or suppressing the symptoms of many autoimmune [2] and skin [3] related diseases such as acne fulminas, actionomycetoma, brown recluse spider bites, celiac disease, cicratical pemphigoid, dermatitis herpetiformis, bullous pemphigoid, Behcet's disease, and lupus erythematous.
One of the main disadvantages of oral administration of dapsone stems from its low solubility and non-specific distribution in the body, once absorbed, it is distributed throughout the organs in the body including skin, liver, and kidneys [4] .
Dapsone has also been reported to cross the blood-brain barrier and the placenta and is found in breast milk [5, 6] . Hence, dapsone therapies are still associated with drawbacks of hemolysis, methemoglobinemia and patient non-compliance [7] . To render the treatment more effective and reduce these side effects, a better control over pharmacokinetics and site specific delivery are needed. Thus far, the design of polymer formulations for controlled delivery of dapsone has been limited to encapsulation within polymeric systems, for which mainly polysaccharides have been used [8, 9] . Although these methodologies have improved the pharmacokinetics, the therapeutic effects of these polymer formulations were found to be modest and a reduction of the complications associated with dapsone therapies were not sufficiently achieved.
Recent developments in the field of polymer-conjugates have provided very promising examples of FDA approved and marketed pharmaceutical products [10] .
Anti-inflammatory therapies involving the incorporation of low molecular weight drugs into macromolecular systems such as ibuprofen and aspirin polymer-drug conjugates have shown promising advances that enhance the bioavailability and compatibility within the body [11, 12] . Nonetheless, biomedical approaches based on dapsone polymer-drug conjugates have not yet been fully exploited. Chemically incorporating 4, 4'-diamino diphenylsulphone (dapsone) into a polymer system has only been reported in elastomeric formulations for engineering applications based on its capacity to act as a curing agent in epoxy resins. This results in a high performance elastomeric material with enhanced thermal and mechanical properties, composite materials, and structural adhesives that are unrelated to the current work [13] .
In view of the limitations of current dapsone treatment, a polymer system that intrinsically contains the active dapsone molecule anchored to the macromolecular polymer structure will be extremely beneficial and efficacious for therapeutic action.
This would lead to enhanced control of pharmacokinetics whilst providing a novel approach for safe use of this promising drug. The covalent linking of dapsone into macromolecular chains is advantageous as it will reduce the migration of dapsone into the surrounding tissues and improve hydrolytic and biological stability. This study reports for the first time the synthesis and characterisation of a polymerisable derivative of dapsone, dapsone methacrylamide (DapMA) (Figure 1) and the polymers thereof. These systems have the potential for the development of bioactive polymeric formulations with anti-inflammatory properties by virtue of the dapsone residues anchored to the macromolecular chains, which have not yet been reported.
Materials and Methods

Chemicals
Dapsone (97 %) was purchased from Aldrich and recrystallised from methanol.
Methacryloyl chloride (97 %, Aldrich) and triethylamine (98 %, Scharlau) were purified by distillation under reduced pressure. 2-Hydroxyethyl methacrylate (HEMA) (97 %, Sigma-Aldrich) was purified according to the literature by water-hexane selective extraction and washing [14] . 2,2-Azobisisobutyronitrile (AIBN) (98 %, Merck) was recrystallised using methanol. Ethylene glycol dimethacrylate (EGDMA) (98%, Aldrich) was used as received. Solvents used were high performance liquid chromatography (HPLC) grade and all other reagents were analytical grade purchased form Sigma-Aldrich.
Phosphate-buffered solution (PBS) of pH 7.4 (Sigma) was used as received.
Thermanox (TMX) control disks were supplied by Labclinics S. L., and aqueous solutions of Triton X-100 were supplied by Aldrich. Tissue culture media, additives, trypsin, and 3-(4,5 dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) were purchased from Sigma. . Tg was taken as the midpoint of the heat capacity transition observed. Thermogravimetric diagrams were obtained using a thermogravimetric analyser using a TGA Q500 (TA instruments) apparatus, under a stream of nitrogen at a heating rate of 5 °C · min -1 from 40 -600 °C.
Synthesis of Dapsone Methacrylamide monomer
In vitro drug release, degradation, cell culture, cytotoxicity and antiinflammatory activity of dapsone derivatives.
In vitro drug release and degradation studies were carried out using crosslinked P100 and P50 disk shaped samples of 12mm in diameter. In vitro dapsone release from each composition was studied by soaking three different crosslinked samples in 2 mL of three different release media at pH 3, 7 and 10 buffered solutions and at 37 °C under continuous agitation using an orbital shaker. At desired time points, the medium was refreshed under sterile conditions. The extracts were mixed with methanol (1:1 v/v) for dapsone release and quantification was done by UV spectroscopy detection at 295 nm using a Perking Elmer Lambda 16 instrument.
Known concentration solutions of dapsone (0 -10 g · mL ) was added to each well and plates incubated at 37 °C for 4 h. The excess medium and MTT were then removed and 100 mL of DMSO was added to each well in order to dissolve the formazan produced by viable cells. The absorbance was measured using a test wavelength of 570 nm (Biotek ELX808 IU detector).
Samples with a cell viability over 70% were selected for the determination of the anti-inflammatory activity by the nitric oxide inhibitory method reported by Wang et al [15] . Briefly, raw cells were seeded at a density of 5 · 10 4 cells · mL 
Results
Dapsone Methacrylamide monomer
Dapsone was functionalised with an acrylic moiety, in which the methacrylamide residue was directly bonded to one of the aromatic rings of dapsone leading to unsymmetrical structure of DapMA forming a white powder with a yield 52% after the recrystallization procedure. The reaction scheme for the acylation of dapsone is illustrated in Figure 2 ).
13
C-NMR spectrum p(DapMA-co-HEMA) (DMSO-d6):
-175.5 (CO-NH, COO), 154.3 (NH 2 -C-CH-CH-C-SO 2 ), 143.3 (CO-NH-C-CH-CH-C-SO 2 ), 138.2 (CO-NH-C-CH-CH-C-SO 2 ), 130.2 (CO-C-CH-CH-C-SO 2 )
128.1 (CO-NH 2 -C-CH-CH-C-SO 2 ) 126.5 (NH 2 -C-CH-CH-C-SO 2 ), 121.8 (CO-NH-C-CH-CH-C-SO 2 ), 113.4 (NH 2 -C-CH-CH-C-SO 2 ), 66. Figure 5 shows the 1 H-NMR spectra of the homopolymer and co-polymer system in which the corresponding signal of each monomeric units could be observed. Co-polymer composition was determined from Molecular weight and polydispersity determined by SEC and thermal characteristic of P100 and P50 polymers are summarized in Table 1 
Characterisation techniques
In vitro dapsone release, degradation, cytotoxicity and anti-inflammatory activity.
Weight loss determined by gravimetric measurements showed that the polymers were stable when immersed in PBS solutions at 37 °C with a weight loss lower than 0.1 % after 21 days. The release of dapsone at three different pHs (acidic, neutral, basic) is shown in Figure 8 . The sustained release profiles of dapsone were comparable at different pH for all polymer conjugates with a slight increase in dapsone release for the P50 copolymers at pH 10. Figure 9 revealing significant inhibition on NO production compared to those of LPS-stimulated control cultures with no polymer drug added. In addition, the incorporation of HEMA into the copolymers reduced their cytotoxicity as observed in (Figure 10 ) for the dosedependent effect with IC50 values ranging between 32 and 43 g·ml-1 ( Table 2 ).
The nitric oxide (NO) inhibitory effects of the dapsone polymers on LPS treated cells after 24 h of incubation is shown in
This revealed the absence of cytotoxic effects (CV > 99%) associated to the polymer extracts used for the NO inhibition studies.
Discussion
A typical acylation reaction was used for the synthesis of the DapMA by reaction with methacryloyl chloride using triethylamine as a catalyst under mild conditions [17] . Since dapsone contains two reactive aromatic amine functional groups it can lead to the formation of an undesirable side product namely bisacrylamide as shown in Figure 1 . However, the yield of this double acylation product could be kept to a minimum by using stoichiometric amounts of the acyl compounds.
The mono functional derivative of the symmetric sulfamides could be easily isolated and both unreacted dapsone and bis-acrylated derivatives were removed using recrystallization techniques [18] . Although a modest yield is obtained, this simple and easy synthetic process of obtaining DapMa did not warrant further optimisation in order to increase the yield since sufficient amounts of the desired monomer could be easily obtained [17] . The 1 H and 13 C NMR peak assignment is presented in Section 3.1 and were further supported by the two-dimensional HMQC spectra ( Figure 4) and by previous works reporting NMR studies on (4-substituted aryl) sulfones which shown peak assignments in concordance with the reported here [19] . The amidation reaction was confirmed by the appearance of the bands corresponding to the methacrylic residue (5.8 and 5.5 ppm) and amide proton (10.1 ppm).
HEMA monomer is known to impart a certain degree of ductility and hydrophilicity to polymeric systems and is beneficial for tuning mechanical and biological properties thus makes it a candidate of choice for biocompatible polymer drug conjugates preparation. Both P100 and P50 linear polymers were characterised by FTIR and The DapMA homo and copolymers were soluble in DMF, and the number average molecular weight values determined by SEC were relatively high (Mn > 50kDa) (Table 1 ) with polydispersity indices near to 2.0 as expected for conventional free-radical reaction processes and therefore confirming this polymerization mechanism proposed.
The four degradation stages of p(DapMA-co-HEMA) copolymer suggested a degradation mechanism similar to the described for analogue acrylic polymers.
According to well established theories [20, 21] , the first stage of degradation originates from sterically hindered linkages that result from head-to-head coupling during polymerisation. The second stage of degradation is attributed to the decomposition of the vinylidene chain end due to disproportionation, with the rest of the stages being attributed to random scission of the main chain leading to depolymerisation of the acrylic polymer. In contrast, the p(DapMA) homopolymer thermogram suggesting the absence of head-to-head coupling reactions during the polymerisation and absence of vinylidene chain ends. The higher stability of p(DapMA) can be associated with the stabilization of the free radicals produced in the thermal degradation due to the presence of dapsone moiety that provide with antioxidant properties associate to its capacity for stabilize free radicals and radical scavenger action [22] . This observation is akin to anti-oxidant properties previously described for dapsone and thus beneficial when the polymer interacts with cells under physiological conditions [23] .
EGDMA constitutes a common reagent for preparing biocompatible crosslinked polymers due to its effectiveness and desired polymerization kinetics [24] . The aim of crosslinking the linear P50 and P100 polymers was to prepare insoluble matrices with a desired size and shape to support the in vitro drug release and degradation experiments. Release of dapsone was studied using a UV detector, which is a simple, fast and practical method with a detection limit of 2 mg · mL -1 [25] .
The results indicated a sustained release from both homopolymer and co-polymer as expected for amide linkages ( Figure 8 ) and were comparable at three different pHs (acidic, neutral, basic) for all polymer conjugates with a slight increase in dapsone release for the P50 copolymers at pH 10. This mechanism indicates that the hydrolysis of the amide groups occurs only along the hydrophobic dapsone sequences and water accessibility is facilitated with the presence of HEMA sequences. It is important to highlight that the time points selected in this study were chosen from an experimental point of view and were not necessarily biologically relevant. However, from a biomedical perspective the hydrolysis mechanism by which the drug can be delivered is highly dependent on many other factors relative to both physical-chemical properties of the polymer drug conjugate, place of action and biological and enzymatic activity of the degradation milieu. Amide linkage constitute a widespread approach of drug conjugation towards the greater control over pharmacokinetics and targeted delivery where the main release mechanism is accepted to be enzymatically mediated (peptidases, matrix metalloproteinase, collagenase, prostate specific membrane antigen, plasmin and others) [26] . The biodegradation rate of vinyl copolymers depends on a number of parameters such as hydrophilicity/hydrophobicity balance, composition, monomer sequence distribution, molecular weight or micro and macrostructure among other biological characteristic of the host tissues which drive the degradation mechanism of the macromolecules within body environments. It is well known that the degradative process of relatively low to medium molecular weight (<100 KDa) (meth)acrylic based copolymers occurs first thought the hydrolysis of lateral residues followed by a random excision of the main backbone leading to a reduction of molecular weight that permit further bioelimination and excretion of degradative products. The copolymers described in this work comprise of well-known biocompatible and bioresorbable hydrocarbon backbones analogues similar to established systems systems such as poly(hydroxymethyl methacylate) and poly(methacrylic acid) that permit us hypothesise an analogue biodegradation mechanism in the body [27] . Meanwhile, gravimetric degradation studies of samples in buffered fluid showed a negligible loss of weight during the course of the experiment, confirming the stability of these materials in aqueous conditions. As a result, the in vitro behaviour of the polymers is a consequence of the macromolecular composition and not only due to the release of low molecular weight compounds. The conjugation of dapsone to macromolecular systems thus provides a synthetic route to incorporate this drug into polymeric systems, with the potential to synthesize polymers with inherent anti-inflammatory action.
The nitric oxide inhibition assay constitutes a well-established method to determine the macrophage mediated in vitro activity of anti-inflammatory polymer drug conjugates. This assay consists in the quantification of NO production in macrophage cultures through activation of inducible nitric oxide synthase by a proinflammatory LPS before the evaluation of NO inhibition activity from extracts of the samples [11, 28] . The inhibitory effects of the dapsone polymers on LPS treated cells indicate good anti-inflammatory response for all samples with NO inhibition (mean ranges P100: 67-83 % and P50 67-90 %) with a maximum NO inhibition capacity between the two copolymers significantly higher for P50 after 24 hours of incubation (p > 0.05), corresponding to a qualitative anti-inflammatory activity order of P50 > P100. This activity sequence indicates that despite HEMA monomer not possessing inflammatory effects by itself, its presence in the macromolecule contributes to a synergistic effect in improving the overall anti-inflammatory capacity of dapsone mainly related to the dapsone release mechanism. In addition, the incorporation of HEMA into the co-polymers reduced their cytotoxicity as resulted from their higher IC50 values.
Conclusions
The synthesis of dapsone-conjugated methacrylic monomer and polymers provides a new approach of obtaining high molecular weight macromolecular systems with in vitro anti-inflammatory properties. This approach will enable exploiting the clinical applications of dapsone further and has great potential in the development of advanced anti-inflammatory therapies. 
